4.4 Article

Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD

期刊

出版社

SPRINGER
DOI: 10.1007/s00417-014-2589-3

关键词

Age-related macular degeneration; Aflibercept; Ranibizumab; Bevacizumab; Tolerance; Tachyphylaxis

资金

  1. Werner H. Spross Foundation for Ophthalmology at the Triemli Hospital Zurich
  2. Bayer AG Switzerland

向作者/读者索取更多资源

Evaluation of three aflibercept injections at 4-week intervals in patients with neovascular AMD showing an insufficient anatomic response to prior anti-VEGF therapy with ranibizumab or bevacizumab. The retrospective analysis included 96 eyes that had received at least three intravitreal 0.5 mg ranibizumab or 1.25 mg bevacizumab injections over a period of no more than 4 months prior to switching to aflibercept. In addition, the selected eyes had to have evidence of persisting or increasing sub- or intraretinal fluid, observed in optical coherence tomography (OCT). All patients received a loading dose of three intravitreal 2 mg aflibercept injections at 4-week intervals. Evaluation included central retinal thickness (CRT) and maximum pigment epithelium (PED) height measured by spectral domain OCT and best-corrected visual acuity (BCVA) prior to the switch of therapy and 4 weeks after the third aflibercept injection. A significant reduction of mean CRT (-39 mu m; p < 0.001) and maximum PED height (-46 mu m; p < 0.001) as found 4 weeks after the third aflibercept injection. Eighty-two out of 96 eyes (85 %) had a PED just prior to switching to aflibercept. There was an improvement in BCVA of 1.9 letters 4 weeks after the last aflibercept injection; the vision gain, however, did not reach statistical significance (p = 0.061). The further analysis did not show any correlation of the change in CRT, maximum PED, and BCVA with the number of prior anti-VEGF treatments. Retinal edema and PEDs regressed significantly after switching to aflibercept in patients insufficiently responding to prior therapy with ranibizumab or bevacizumab. No correlation could be found with regard to the number of prior treatments.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据